TOP TEN perturbations for 39431_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39431_at
Selected probe(set): 201455_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39431_at (201455_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-2.877634Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
esophageal squamous cell carcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-2.4009457Number of Samples:8 / 18
Experimental | esophageal squamous cell carcinoma study 1 |
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. | |
Control | normal esophageal epithelium sample |
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.3982906Number of Samples:2 / 2
Experimental | phenobarbital study 3 (10000uM) |
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code: | |
Control | vehicle (medium) treated hepatocyte sample |
Hepatocytes treated with vehicle (medium) for 24 hours. |
phenobarbital study 2 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.1287727Number of Samples:2 / 2
Experimental | phenobarbital study 2 (10000uM) |
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 8 hours. ATC code: | |
Control | vehicle (medium) treated hepatocyte sample |
Hepatocytes treated with vehicle (medium) for 8 hours. |
esophageal adenocarcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-1.9802818Number of Samples:20 / 18
Experimental | esophageal adenocarcinoma study 1 |
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique. | |
Control | normal esophageal epithelium sample |
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):-1.9173422Number of Samples:15 / 2
Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
Control | uterine/pelvic pathology study 2 (late se MCP) |
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):-1.8325901Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):1.764741Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-1.6842117Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-1.682025Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |